---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-005260"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:34:30.858061+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Compass Q2 net loss $19.9M; CTX-8371 shows deep responses; tovecimig OS readout moves to Q1 2026

## Summary
- Net loss Q2 2025 $19.9M ($0.14/share) vs $13.1M ($0.10/share) in Q2 2024; R&D expenses rose 47% to $16.4M.
- Tovecimig Ph2/3 BTC trial met primary endpoint (ORR 17.1% vs 5.3%, p=0.031); OS analysis delayed to Q1 2026 due to fewer deaths.
- CTX-8371 Ph1: confirmed PR in NSCLC with 100% target lesion reduction and TNBC with >90% reduction; expansion cohorts planned Q4 2025.
- CTX-10726 (PD-1 x VEGF-A) showed superior PD-1 inhibition and tumor control vs ivonescimab preclinically; IND filing on track for Q4 2025.
- Cash and marketable securities $101M as of June 30, 2025; expected cash runway into 2027.

## SEC filing metadata
- accession: 0001171843-25-005260
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184325005260/0001171843-25-005260-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184325005260/f8k_080925.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-005260
- JSON: https://secwatch.observer/filing/0001171843-25-005260.json
- Plain text: https://secwatch.observer/filing/0001171843-25-005260.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.